antiparkinson agents

Preferred Label : antiparkinson agents;

MeSH definition : Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.;

MeSH synonym : antiparkinsonians; agents, antiparkinsonian; drugs, antiparkinson; antiparkinson drugs; antiparkinsonian agents; agents, antiparkinson;

MeSH annotation : GEN or unspecified; prefer specifics; consider also PARKINSON DISEASE /drug ther; general or unspecified; prefer specifics;

Is substance : O;

action pharmacologique : O;

Details

Origin ID

D000978;

UMLS CUI

C0003405;

ATC code(s)
- dopamine agonists [ATC Code]
- melevodopa [ATC Code]
ATC code(s)
- amantadine [ATC Code]
- anti-parkinson drugs [ATC Code]
- apomorphine [ATC Code]
- benzatropine [ATC Code]
- biperiden [ATC Code]
- bornaprine [ATC Code]
- bromocriptine [ATC Code]
- budipine [ATC Code]
- cabergoline [ATC Code]
- dexetimide [ATC Code]
- dopaminergic agents [ATC Code]
- etanautine [ATC Code]
- etybenzatropine [ATC Code]
- levodopa [ATC Code]
- levodopa and decarboxylase inhibitor [ATC Code]
- mazaticol [ATC Code]
- metixene [ATC Code]
- monoamine oxidase b inhibitors [ATC Code]
- orphenadrine (chloride) [ATC Code]
- pergolide [ATC Code]
- phenglutarimide [ATC Code]
- piribedil [ATC Code]
- pramipexole [ATC Code]
- procyclidine [ATC Code]
- profenamine [ATC Code]
- rasagiline [ATC Code]
- ropinirole [ATC Code]
- selegiline [ATC Code]
- tolcapone [ATC Code]
- trihexyphenidyl [ATC Code]
- tropatepine [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Currated CISMeF NLP mapping
- Antiparkinsonian Agent [NCIt concept]
- Antiparkinsonian agent (substance) [SNOMED CT concept]
- Antiparkinsonism drug [ICD-11 Extension code]
- anti-parkinson drugs [ATC Code]
- antiparkinson agent [Disease (Nov.)]
- antiparkinsonian agent, nos [SNOMED Notion]
Indexing information
- 3-O-demethylswertipunicoside [MeSH Supplementary Concept]
- 7-(4-benzyl-1-piperazinyl)-2(3H)-benzoxazolone methanesulfonate [MeSH Supplementary Concept]
- ACS 84 [MeSH Supplementary Concept]
- IRC-082451 [MeSH Supplementary Concept]
- ifenprodil [MeSH Supplementary Concept]
- isopropyl 2-(2-amino-2-methylpropanamido)-3-(3,4-dihydroxyphenyl)propanoate [MeSH Supplementary Concept]
Record concept(s)
- antiparkinson agents [MeSH concept]
See also
- parasympatholytics [MeSH Descriptor]
See also (suggested by CISMeF)
- parkinson disease [MeSH Descriptor]
- parkinsonian disorders [MeSH Descriptor]
See also inter- (CISMeF)
- Medicinal product acting as antiparkinson agent (product) [SNOMED CT concept]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
Substance(s)
- A 77636 [MeSH Supplementary Concept]
- CY 208-243 [MeSH Supplementary Concept]
- Cabergoline [MeSH Descriptor]
- DPI-289 [MeSH Supplementary Concept]
- LY 235959 [MeSH Supplementary Concept]
- N-n-propylnorapomorphine [MeSH Supplementary Concept]
- Pramipexole [MeSH Descriptor]
- amantadine [MeSH Descriptor]
- benserazide [MeSH Descriptor]
- benztropine [MeSH Descriptor]
- biperiden [MeSH Descriptor]
- biperiden lactate [MeSH Supplementary Concept]
- bromocriptine [MeSH Descriptor]
- budipine [MeSH Supplementary Concept]
- carbidopa, levodopa drug combination [MeSH Supplementary Concept]
- dexetimide [MeSH Descriptor]
- dopa decarboxylase [MeSH Descriptor]
- droxidopa [MeSH Descriptor]
- lazabemide [MeSH Supplementary Concept]
- levodopa [MeSH Descriptor]
- levodopa methyl ester [MeSH Supplementary Concept]
- lisuride [MeSH Descriptor]
- memantine [MeSH Descriptor]
- mesulergine [MeSH Supplementary Concept]
- mofegiline [MeSH Supplementary Concept]
- orphenadrine [MeSH Descriptor]
- pimavanserin [MeSH Supplementary Concept]
- piribedil [MeSH Descriptor]
- preclamol [MeSH Supplementary Concept]
- procyclidine [MeSH Descriptor]
- progabide [MeSH Supplementary Concept]
- ropinirole [MeSH Supplementary Concept]
- selegiline [MeSH Descriptor]
- trihexyphenidyl [MeSH Descriptor]
UMLS correspondences (same concept)
- Antiparkinsonian [LOINC hierarchical part]
- Antiparkinsonian Agent [NCIt concept]
- Antiparkinsonian agent (substance) [SNOMED CT concept]
- Antiparkinsonism drug [ICD-11 Extension code]
- Medicinal product acting as antiparkinson agent (product) [SNOMED CT concept]
- anti-parkinson drugs [ATC Code]
- antiparkinson agent [Disease (Nov.)]
- antiparkinsonian agent, nos [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients